Studies have attempted to utilize MPCs or MSCs for the treatment of arthritis and inflammation-induced joint injuries (such as articular cartilage damage) (Kurose et al., 2010), and have demonstrated that the therapeutic efficacy of MPCs and MSCs may be associated with the high expression of CD10. This evidence concerns the gene MME and arthritic joint disease.